Inventage Lab

Inventage Lab Free Cash Flow

The Free Cash Flow (FCF) of Inventage Lab (389470.KQ) as of Nov 3, 2026 is -27.57 B KRW. In the previous year, Free Cash Flow (FCF) was -17.98 B KRW — a change of 53.31% (lower).

Free Cash Flow

-27.57 BKRW

YoY

53.31%

Last updated:

Free Cash Flow (FCF) of Inventage Lab is 2025 -27.57 B KRW. Free Cash Flow (FCF) of Inventage Lab was 2024 -17.98 B KRW. It decreases by 53.31% lower compared to the previous year.

The Inventage Lab Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2019
-7.17 B KRW
Jan 1, 2020
-5.63 B KRW
Jan 1, 2021
-11.01 B KRW
Jan 1, 2022
-7.17 B KRW
Jan 1, 2023
-18.85 B KRW
Jan 1, 2024
-17.98 B KRW
Jan 1, 2025
-27.57 B KRW
The Inventage Lab Free Cash Flow history
YEARFree Cash FlowYoY
-27.57 BKRW+53.31%
-17.98 BKRW-4.60%
-18.85 BKRW+162.97%
-7.17 BKRW-34.89%
-11.01 BKRW+95.67%
-5.63 BKRW-21.48%
-7.17 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

Free Cash Flow (FCF) of Inventage Lab is -27.57 B KRW in 2025.

Free Cash Flow (FCF) of Inventage Lab changed from -17.98 B KRW to -27.57 B KRW, representing a 53.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Inventage Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Inventage Lab

All Key Metrics — Inventage Lab